SG11201901249YA - Aza-indazole compounds for use in tendon and/or ligament injuries - Google Patents
Aza-indazole compounds for use in tendon and/or ligament injuriesInfo
- Publication number
- SG11201901249YA SG11201901249YA SG11201901249YA SG11201901249YA SG11201901249YA SG 11201901249Y A SG11201901249Y A SG 11201901249YA SG 11201901249Y A SG11201901249Y A SG 11201901249YA SG 11201901249Y A SG11201901249Y A SG 11201901249YA SG 11201901249Y A SG11201901249Y A SG 11201901249YA
- Authority
- SG
- Singapore
- Prior art keywords
- novartis
- basel
- postfach
- pharma
- research
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 29 March 2018 (29.03.2018) WIPO I PCT 0111111010 0111 °nolo III um VIII O II oimIE (10) International Publication Number WO 2018/055551 Al (51) International Patent Classification: CO7D 471/04 (2006.01) A61P 19/02 (2006.01) A61K 31/437 (2006.01) (21) International Application Number: PCT/IB2017/055737 (22) International Filing Date: 21 September 2017 (21.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/398,865 23 September 2016 (23.09.2016) US (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). (72) Inventors: BURSULAYA, Badry; Novartis Institute for Functional Genomics, Inc., dba, Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121 (US). FISCH, Andreas; No- vartis Pharma AG, Postfach, 4002 Basel (CH). LAJINESS, James Paul; Novartis Institute for Functional Genomics, Inc., dba, Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121 (US). MACHAUER, Rainer; Novartis Pharma AG, NIBR Klybeck, Postfach, 4002 Basel (CH). MALEKAR, Swapnil; Novartis Institutes for BioMedical Research, Inc., Emeryville Site 5300 Chiron Way, Bldg. 4, Emeryville, CA 94608 (US). PETRASSI, Hank Michael James; 4695 Ser- enata Place, San Diego, CA 92130 (US). RAMAZANI, Farshad; Novartis Pharma AG, Postfach, 4002 Basel (CH). REMOND, Anne-Catherine; Novartis Pharma AG, No- vartis Institutes for Biomed. Research, Postfach, 4002 Basel (CH). ULLRICH, Thomas; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, 4002 Basel (CH). USSELMANN, Peggy; Novartis Pharma AG, Novartis In- stitutes for Biomed. Research, Postfach, 4002 Basel (CH). VANGREVELINGHE, Eric; Novartis Pharma AG, No- vartis Institutes for Biomed. Research, Postfach, 4002 Basel (CH). (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4056 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) W O 20 18/05555 1 Al (54) Title: AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES (57) : The present invention provides a compound of formula (I) in free form or in pharma- ceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. (I)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398865P | 2016-09-23 | 2016-09-23 | |
| PCT/IB2017/055737 WO2018055551A1 (en) | 2016-09-23 | 2017-09-21 | Aza-indazole compounds for use in tendon and/or ligament injuries |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901249YA true SG11201901249YA (en) | 2019-04-29 |
Family
ID=60164748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901249YA SG11201901249YA (en) | 2016-09-23 | 2017-09-21 | Aza-indazole compounds for use in tendon and/or ligament injuries |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10766894B2 (en) |
| EP (1) | EP3515913B1 (en) |
| JP (1) | JP7008065B2 (en) |
| KR (1) | KR102472017B1 (en) |
| CN (1) | CN109715629B (en) |
| AU (1) | AU2017332868B2 (en) |
| BR (1) | BR112019005318A2 (en) |
| CA (1) | CA3033253A1 (en) |
| CL (1) | CL2019000768A1 (en) |
| CO (1) | CO2019002618A2 (en) |
| CR (1) | CR20190144A (en) |
| CU (1) | CU24550B1 (en) |
| DO (1) | DOP2019000070A (en) |
| EA (1) | EA039908B1 (en) |
| EC (1) | ECSP19019613A (en) |
| ES (1) | ES2924104T3 (en) |
| IL (1) | IL264763B (en) |
| JO (1) | JOP20190053A1 (en) |
| MX (1) | MX2019003373A (en) |
| MY (1) | MY197464A (en) |
| PE (1) | PE20191006A1 (en) |
| PH (1) | PH12019500328A1 (en) |
| RU (1) | RU2758256C2 (en) |
| SG (1) | SG11201901249YA (en) |
| WO (1) | WO2018055551A1 (en) |
| ZA (1) | ZA201900861B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190053A1 (en) * | 2016-09-23 | 2019-03-21 | Novartis Ag | Aza-indazole compounds for use in tendon and/or ligament injuries |
| JOP20190144A1 (en) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
| TW202016110A (en) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Small molecule inhibitors of the jak family of kinases |
| GB201813312D0 (en) | 2018-08-15 | 2018-09-26 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| WO2020144604A1 (en) | 2019-01-11 | 2020-07-16 | Novartis Ag | Lta4h inhibitors for the treatment of hidradenitis suppurativa |
| TW202342048A (en) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | Methods of treating hidradenitis suppurativa using lou064 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105532B2 (en) | 2000-12-19 | 2006-09-12 | Smithkline Beecham Corporation | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| FR2871158A1 (en) | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE |
| DE102004028862A1 (en) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-aminoindazoles |
| TW200616967A (en) | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
| FR2889526B1 (en) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE |
| US9554319B2 (en) * | 2005-09-27 | 2017-01-24 | Qualcomm Incorporated | Channel handoff methods in wireless broadcast systems |
| WO2008104473A2 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Pyrazolopyriidine derivatives and their use as kinase inhibitors |
| BRPI0811065A2 (en) | 2007-06-08 | 2014-12-02 | Abbott Lab | 5-HETEROARYL INDAZOES REPLACED AS KINASE INHIBITORS |
| WO2010068287A2 (en) | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| EP2789615B1 (en) | 2009-08-11 | 2017-05-03 | Bristol-Myers Squibb Company | Azaindazoles as Btk kinase modulators and use thereof |
| US9556201B2 (en) * | 2009-10-29 | 2017-01-31 | Glaxosmithkline Llc | Bicyclic pyridines and analogs as sirtuin modulators |
| JP2013542960A (en) | 2010-11-08 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | Fatty acid synthase inhibitor |
| US20140107151A1 (en) | 2011-05-17 | 2014-04-17 | Principia Biophama Inc. | Tyrosine kinase inhibitors |
| UA112028C2 (en) * | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | IMIDAZOPYRIDASINE DERIVATIVES AS HAMBA-RECEPTOR MODULATORS |
| TWI629275B (en) * | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | N-(4-azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals |
| CN105991238A (en) | 2015-03-06 | 2016-10-05 | 中兴通讯股份有限公司 | Measurement and feedback method of channel state information, sending end, and receiving end |
| WO2016161571A1 (en) * | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Indazole and azaindazole btk inhibitors |
| UY37412A (en) * | 2016-09-23 | 2018-04-30 | Novartis Ag | INDAZOL COMPOUNDS FOR USE IN INJURY OF TENDONS AND / OR LIGAMENTS |
| JOP20190053A1 (en) * | 2016-09-23 | 2019-03-21 | Novartis Ag | Aza-indazole compounds for use in tendon and/or ligament injuries |
-
2017
- 2017-06-16 JO JOP/2019/0053A patent/JOP20190053A1/en unknown
- 2017-09-21 JP JP2019515597A patent/JP7008065B2/en active Active
- 2017-09-21 MY MYPI2019000712A patent/MY197464A/en unknown
- 2017-09-21 EA EA201990765A patent/EA039908B1/en unknown
- 2017-09-21 CA CA3033253A patent/CA3033253A1/en active Pending
- 2017-09-21 PE PE2019000681A patent/PE20191006A1/en unknown
- 2017-09-21 CU CU2019000029A patent/CU24550B1/en unknown
- 2017-09-21 EP EP17788297.4A patent/EP3515913B1/en active Active
- 2017-09-21 US US16/335,496 patent/US10766894B2/en active Active
- 2017-09-21 MX MX2019003373A patent/MX2019003373A/en unknown
- 2017-09-21 WO PCT/IB2017/055737 patent/WO2018055551A1/en unknown
- 2017-09-21 BR BR112019005318A patent/BR112019005318A2/en active Search and Examination
- 2017-09-21 KR KR1020197010513A patent/KR102472017B1/en active IP Right Grant
- 2017-09-21 ES ES17788297T patent/ES2924104T3/en active Active
- 2017-09-21 CN CN201780057672.8A patent/CN109715629B/en active Active
- 2017-09-21 CR CR20190144A patent/CR20190144A/en unknown
- 2017-09-21 SG SG11201901249YA patent/SG11201901249YA/en unknown
- 2017-09-21 RU RU2019111886A patent/RU2758256C2/en active
- 2017-09-21 AU AU2017332868A patent/AU2017332868B2/en not_active Ceased
-
2019
- 2019-02-10 IL IL264763A patent/IL264763B/en active IP Right Grant
- 2019-02-11 ZA ZA2019/00861A patent/ZA201900861B/en unknown
- 2019-02-15 PH PH12019500328A patent/PH12019500328A1/en unknown
- 2019-03-20 DO DO2019000070A patent/DOP2019000070A/en unknown
- 2019-03-20 EC ECSENADI201919613A patent/ECSP19019613A/en unknown
- 2019-03-21 CO CONC2019/0002618A patent/CO2019002618A2/en unknown
- 2019-03-22 CL CL2019000768A patent/CL2019000768A1/en unknown
-
2020
- 2020-07-28 US US16/941,395 patent/US11203595B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201908740VA (en) | Sustained release delivery systems comprising traceless linkers | |
| SG11201900482SA (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906417RA (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201908660RA (en) | N-substituted indole derivatives | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201908097YA (en) | Pyrimidine derivatives as pge2 receptor modulators | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201900651PA (en) | Combination of fxr agonists | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase |